ReviewTranslational lung cancer research2026
Current advances in extended resections for non-small cell lung cancer-a narrative review.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Locally advanced non-small cell lung cancer (NSCLC) encompasses a biologically and anatomically highly heterogenous spectrum. For tumours with infiltration of the chest wall, thoracic inlet, central airways, great vessels, diaphragm or vertebral column, the goal of surgery remains a complete R0 resection, but the boundary between resectable and unresectable disease is fluid and depends on anatomy, nodal burden, response to induction therapy, functional reserve as well as institutional experience. This review summarizes current concepts in extended resection and proposes a practical framework for patient selection. Methods: We performed a narrative review of literature indexed in PubMed, Embase, Scopus and Google Scholar from January 2000 to January 2026. Priority was given to guidelines, expert consensus statements, prospective studies, systematic reviews/meta-analyses, and recent multicentre or large institutional series. Evidence was synthesized narratively with emphasis on resectability, patient selection, operative strategy and oncologic outcomes. Key Content and Findings: Extended resection is defined as anatomical pulmonary resection combined with Conclusions: Extended resection for locally advanced NSCLC should be considered a tailored multidisciplinary strategy rather than a purely technical exercise. The best candidates are those in whom multimodal therapy can provide an R0 resection with acceptable perioperative risk. Future work should focus on refining resectability criteria, incorporating biological response markers to immunotherapy into decision-making, and prospectively evaluating salvage strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.